(Dihydro) isoquinoline derivatives as phosphodiesterase...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C546S144000, C514S307000

Reexamination Certificate

active

06818651

ABSTRACT:

USE OF THE INVENTION
The invention relates to novel phosphodiesterase inhibitors which are used in the pharmaceutical industry for producing drugs.
KNOWN TECHNICAL BACKGROUND
Journal of Medicinal Chemistry 1979, Vol. 22, No. 4, pp. 348-352 describes, inter alia, 6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinolines which inhibit cAMP phosphodiesterases better than does the non-specific PDE inhibitor theophylline. In International Patent Application WO 99/44609 fused piperidine substituted arylsulfonamides are disclosed which are said to have potent activity in the treatment of Type II diabetes and obesity.


REFERENCES:
patent: 6043263 (2000-03-01), Bar et al.
patent: 0 490 823 (1992-06-01), None
patent: 0 664 289 (1995-07-01), None
patent: 94/10118 (1994-05-01), None
patent: 89/08830 (1998-03-01), None
patent: 98/55481 (1998-12-01), None
patent: 99/44609 (1999-09-01), None
Walker, K.A., et al. “1-(4-Aminobenzyl)- and 1-(4-Aminophenyl) isoquinoline Derivatives: Synthesis and Evaluation as Potential Irreversible Cyclic Nucleotide Phosphodiesterase Inhibitors”, Journal of Medicinal Chemistry , vol. 26, No. 2, pp. 174-181, 1983.*
Caplus AN: 1999:123896, abstract of Fuhrmann, et al “Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells,” American Journal of Respiratory Cell and Molecular Biology (1999), 20(2), 292-302.*
Walker, K.A., et al., “1—(4-Aminobenzyl)—and 1—(4-Aminophenyl) isoquinoline Derivatives: Synthesis and Evaluation as Potential Irreversible Cyclic Neucleotide Phosphodiesterase Inhibitors”,Journal of Medicinal Chemistry, vol. 26, No. 2, pp. 174-181, (1983).
Han, P., et al., “Alternative Splicing of the High Affinity CAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart”,Journal of Biological Chemistry, vol. 272, No. 26, pp. 16152-16157, (1997).
Li, L., et al., “CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation”, Science, vol. 283, pp. 848-851, (Feb. 5, 1999).
Sasaki, T., et al., “Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase”,Biochemical and Biophysical Research Communications, vol. 271, No. 3, pp. 575-583, (2000).
St. Georgiev, V., et al., “Drug-Induced Modifications of the Immune Response. 1. Substituted 1-Phenylisoquinolines”,Journal of Medicinal Chemistry, vol. 22, No. 4, pp. 348-352, (1979).
Michaeli, T., et al., “Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficientSaccharomyces cerevisiae”, The Journal of Biological Chemistry, vol. 268, No. 17, pp. 12925-12932, (Jun. 15, 1993).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

(Dihydro) isoquinoline derivatives as phosphodiesterase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with (Dihydro) isoquinoline derivatives as phosphodiesterase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Dihydro) isoquinoline derivatives as phosphodiesterase... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3328864

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.